Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr. David Jin tells Proactive the New Jersey-based company has reached a 'major clinical milestone' by beginning the first-in-human Phase I clinical trial of its flagship AVA-001 therapy in China to treat relapsed/refractory B-cell malignancies, including B-cell lymphoblastic leukemia and non-Hodgkin’s Lymphoma.
Dr. Jin says the clinical trial is being conducted at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China, which he says is the world’s single largest CAR-T treatment network with over 600 patients.
